Congress Abstracts
Total Page:16
File Type:pdf, Size:1020Kb
European Journal of Palliative Care THE JOURNAL OF THE EUROPEAN ASSOCIATION FOR PALLIATIVE CARE Committed to People $0/(3&44 0' 5)& &6301&"/ "440$*"5*0/ '03 1"--*"5*7& $"3& UI o UI .": 7*&//" " 6 4 5 3 * " Abstracts EUROPEAN AUSTRIAN ASSOCIATION FOR SOCIETY FOR PALLIATIVE PALLIATIVE EAPC CARE CARE AB3069_Abstral European Media schedule.qxd:AB3069-EJPalliativeCare-Abstral 12/3/09 14:52 Page 2 TO HELL AND BACK IN MINUTES. FAST ACTING, 1 SHORT LASTING 2 ® Dissolves in seconds. 3 Acts in minutes 1 Abstral® M Abbreviated Prescribing Information sedative H1 antihistamines, barbiturates, anxiolytics, hypnotics, antipsychotics, Abstral® M 100 micrograms, 200 micrograms, 300 micrograms, 400 micrograms, clonidine and related substances may produce increased CNS depressant effects. 600 micrograms and 800 micrograms Sublingual Tablets (fentanyl) Respiratory depression, hypotension and sedation may occur. Concomitant use of Abbreviated Prescribing Information alcohol or partial opioid agonists/antagonists (e.g. buprenorphine, pentazocine) is not Please refer to Summary of Product Characteristics before prescribing. recommended. Not recommended for use in patients who have received MAO inhibitors within 14 days. Pregnancy: Safety in pregnancy not established. Use only Presentation: Sublingual tablets containing 100 µg, 200 µg, 300 µg, 400 µg, 600 µg and when necessary. Long-term treatment may cause withdrawal symptoms in newborn 800 µg of fentanyl. Indication: Management of breakthrough pain in adult patients infant. Do not use during labour and delivery since fentanyl crosses the placenta and using opioid therapy for chronic cancer pain. Dosage and Administration: Only for may cause respiratory depression in foetus or infant. Lactation: Fentanyl is excreted use in patients who are considered tolerant to their opioid therapy for persistent into breast milk and should only be used if the benefits clearly outweigh the potential cancer pain (i.e. using 60 mg oral morphine per day or 25 micrograms transdermal risks for both mother and child. Driving, etc: Fentanyl may impair mental or physical fentanyl per hour or equivalent). Administer directly under the tongue and allow to ability. Advise patients not to drive or operate machinery if they become dizzy, drowsy dissolve without chewing, sucking or swallowing. Adults: Initially 100 µg, titrating or experience blurred or double vision. Undesirable Effects: Typical opioid side-effects upwards as necessary. Patients must be monitored closely by a health professional are to be expected. The most serious adverse reactions are respiratory depression, during the titration process. Once an appropriate dose has been established patients hypotension and shock. The most commonly reported adverse reactions include should be maintained on this dose and should limit consumption to a maximum of four nausea, vomiting, constipation, headache, somnolence/fatigue and dizziness. See doses per day. Elderly and patients with renal and hepatic impairment: Special care SPC for details of these and other undesirable effects. Overdose: Immediate needed in titrating elderly patients and patients with kidney or liver dysfunction; management includes removal of any remaining tablets from the mouth, physical observe for signs of fentanyl toxicity Children and adolescents: Must not be used in and verbal stimulation and an assessment of the level of consciousness. A patent patients less than 18 years of age. Contraindications: Hypersensitivity to any of the airway should be established and maintained, and assisted ventilation initiated if ingredients; opioid-naïve patients; severe respiratory depression or severe obstructive appropriate. Adequate body temperature and parenteral fluid intake should be lung conditions. Warnings and Precautions: Instruct patients and carers to keep maintained. Consider the use of opioid antagonists. Pack Size and Basic NHS Price: tablets out the sight and reach of children. Ensure patients and carers follow Abstral 100-400 µg 10 tablets: £49.99 Abstral 100-800 µg 30 tablets: £149.70. instructions for use and know what action to take in case of overdose. Before Marketing Authorisation Numbers: PL 16508/0030-35. Legal category CD POM. starting Abstral, ensure long-acting opioid treatment for persistent pain is stable. Further information is available from the Marketing Authorisation Holder ProStrakan Dependence may develop upon repeated administration of opioids. Risk of clinically Ltd, Galashiels, TD1 1QH, UK Date of PI Preparation September 2008. significant respiratory depression. Particular caution needed during dose titration in patients with COPD or other conditions predisposing to respiratory depression. Administer with extreme caution in patients who may be particularly susceptible to the Adverse events should be reported. Reporting forms and intracranial effects of hypercapnia. Opioids may mask the clinical course in patients information can be found at www.yellowcard.gov.uk. Adverse with head injuries. Use with caution in patients with bradyarrhythmias, hypovolaemia, events should also be reported to ProStrakan Ltd on 01896 664000 hypotension, mouth wounds or mucositis. Monitor carefully use in elderly, cachectic and debilitated patients. Possible symptoms of withdrawal on cessation are anxiety, References tremor, sweating, paleness, nausea and vomiting. Interactions: Fentanyl is 1. Data on file - Study EN3267-005. metabolised by CYP3A4. Use with caution if given concomitantly with CYP3A4 2. Lennernäs B et al. Br J Clin Pharmacol 2005; 59 (2): 249-253. inhibitors such as macrolide antibiotics, azole antifungal agents, protease inhibitors or 3. Bredenberg S et al . Eur J Pharm Sci 2003; 20 : 327-334. grapefruit juice. Concomitant use of other CNS depressants, such as other morphine IM-M017/0054b derivatives, general anaesthetics, skeletal muscle relaxants, sedative antidepressants, Date of preparation: March 2009 Plenary X EAPC ONLUS 11th Congress of the European Association for Palliative Care (EAPC) Vienna, Austria, 7–10 May 2009 ABSTRACTS EAPC Istituto Nazionale dei Tumori Via Venezian 1 20133 Milan ITALY Tel: +39 02 2390 3390 Fax: +39 02 2390 3393 www.eapcnet.org Published by Hayward Medical Communications, publishers of the European Journal of Palliative Care a division of Hayward Group Ltd, The Pines, Fordham Road, Newmarket CB8 7LG, UK. Printed by Latimer Trend, UK 11th Congress of the European Association for Palliative Care, Vienna, Austria, 7–10 May 2009 3 ForewordPlenary X Dear Congress participant Welcome to Vienna 2009! It is with great pleasure that we present you with this book of abstracts, published by the European Journal of Palliative Care. This book offers a complete guide to the scientific programme of the 11th Congress of the European Association for Palliative Care (EAPC). The programme has been put together through the collaborative work of the Scientific Committee and a very active International Multidisciplinary Advisory Board, and represents two years of planning, preparation, review and sometimes difficult decisions. We could not have produced it without the support of Heidi Blumhuber (EAPC) and Sandrina Josephs (INTERPLAN), whom we thank for their support, guidance and patience. This Congress is entitled ‘Committed to People’. As Chairs of the Scientific Committee, our commitment is to offer you a dynamic and innovative scholarly programme that reflects contemporary palliative care. We – a physician and a nurse involved in the delivery of palliative care through clinical practice, research and education – have worked together in partnership to ensure that we would match the ethos that has become the EAPC’s – One Voice, One Vision. The programme reflects the values and aspirations of all those involved in palliative care. We hope it will give you an opportunity to learn from each other, as we have done ourselves in preparing this Congress. Our pre-conference workshops and ‘Meet the Expert’ sessions will provide both the science and art of palliative care, from genetics to music therapy, from understanding palliative care needs to current policy and practice. For the first time in an EAPC congress, the needs of volunteers will also be included. We have brought together an international array of experts, who will share with you their work and their passion for palliative care. You will hear them in our ‘Plenary’ and ‘Invited Speaker’ sessions. We are particularly delighted that many editors of key international palliative care journals will be joining us. This Congress will offer didactic lectures, opportunities for discussion, and presentations demonstrating current advances in terms of research, education and policy. Using art and drama, we will try to unfold the rich tapestry that expresses the reality of 21st century end-of-life caring. Poster presentations are a key part of this Congress. Over two days, about 900 posters will show the wealth of knowledge that now exists in the field of palliative care. As in previous congresses, the best posters will be awarded prizes in recognition of their scientific merit. 4 11th Congress of the European Association for Palliative Care, Vienna, Austria, 7–10 May 2009 Foreword We invite you to take part in this interesting programme, and to join in with the many delegates from around the world in celebrating our palliative care heritage, here in this magnificent city of Vienna. Vienna is a wonderful city, full of history and beauty, and we hope you will take the time to visit it. It is also appropriate that we remember